Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2821656 | 0.79 | TBXAS1 (0.36) | MAPTPOLBALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL3465068 | 0.79 | THRB (0.38) | MAPTPOLBALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL3467076 | 0.79 | THRB (0.36) | MAPTPOLBALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL2822454 | 0.77 | PPARA (0.40) | MAPTPOLBALDH1A1KMT2AGAA | |
| SCHEMBL2820072 | 0.76 | ALDH1A1 (0.35) | MAPTPOLBALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL2821506 | 0.69 | SMN1; SMN2 (0.50) | MAPTPOLBALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL2819721 | 0.67 | PPARA (0.49) | — | |
| SCHEMBL2822650 | 0.67 | PPARA (0.46) | MAPTALDH1A1KDM4E | |
| SCHEMBL2819988 | 0.66 | SMN1; SMN2 (0.41) | MAPTPOLBALDH1A1KMT2AGAA | |
| SCHEMBL2820147 | 0.65 | ALDH1A1 (0.37) | MAPTPOLBALDH1A1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184815-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2010-07-22 | — | — | US | claimed |
| US-20100184815-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184815-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA | PPARA, PPARD, PPARG | MAPT 4229/4885POLB 598/4885ALDH1A1 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.